- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Antithrombotic Therapy
The Practical Cardiology™ Antithrombotic Therapy clinical resource center offers updates and information about the latest in the fields of antiplatelet and anticoagulation therapy. On this page you will find content related to FDA approvals and the latest information for preventing thrombosis in the form of articles, video interviews with leading experts, clinician-authored columns, and more.
ESC Congress 2021: Top Trials Slideshow
August 31, 2021
Every year, ESC Congress provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for new trials from ESC Congress 2021 conference includes EMPEROR-Preserved, FIGARO-DKD, SSaSS, MASTER DAPT, and the LOOP Study.
ENVISAGE-TAVI AF: Clinical Implications and Next Steps, With George Dangas, MD, PhD
August 31, 2021
George Dangas, MD, PhD, discusses the results of ENVISAGE-TAVI AF and provides perspective into the priorities of investigators as they plan and conduct additional analyses of the trial.
TWILIGHT-Stent: Results Consistent Regardless of Stent Type
August 31, 2021
Results of the TWILIGHT-Stent study provide insight into the impact of stent type on effects of ticagrelor monotherapy compared against ticagrelor plus aspirin among patients within the original TWILIGHT trial.
Ticagrelor Monotherapy Reduces Bleeding Events vs DAPT with Aspirin in HBR Patients
August 30, 2021
TWILIGHT-HBR suggests ticagrelor monotherapy could lower bleeding risk among patients meeting ARC-HBR criteria. Study presenter Davide Cao, MD, offers further perspective on results of the post hoc analysis.
TWILIGHT Analysis Suggests Ticagrelor Monotherapy Preferable in Concomitant Diabetes and CKD
August 30, 2021
A post hoc analysis of the TWILIGHT trial suggests the effects of ticagrelor monotherapy observed in the overall trial were consistent, irrespective of diabetes and chronic kidney disease status.
MASTER DAPT: One-Month of DAPT Benefits Patients with High Bleeding Risk Following Stenting
August 28, 2021
Results of MASTER DAPT demonstrate an abbreviated period of DAPT rather than a standard approach preserves ischemic benefits and reduces bleeding risk in patients at a high bleeding risk following stent implantation.
FDA Approves Rivaroxaban for Use After Lower Extremity Revascularization in Peripheral Artery Disease
August 24, 2021
Announced on August 24, rivaroxaban (Xarelto) has received its ninth indication from the US FDA. This time, the FDA has approved a label expansion to include patients with symptomatic peripheral artery disease who have undergone lower extremity revascularization.
In High-Risk Patients, Most DOACs Reduce Stroke Risk Without Increasing Bleeding Risk vs Warfarin
August 16, 2021
Using propensity score-matching, a new study is providing insight into the risk reduction and bleeding risk associated with various DOACs versus warfarin and one another in patients with nonvalvular atrial fibrillation and an increased gastrointestinal bleeding risk.
Heparin Examined for Potential in COVID-19 in Multiple Trials
August 13, 2021
A trio of trials examine whether or not heparin could provide relief of COVID-19 symptoms in patients with varying levels of disease severity.
Cardiology Month in Review: July 2021
July 31, 2021
July's month in review features stories related to EMPEROR-Preserved meeting primary endpoint, a Q&A with Javed Butler, MD, on heart failure prevention, comparing ACEs vs ARBs, and more. Check back around the end of each month for the next Cardiology Month in Review.